BioCentury | Jan 25, 2020
Product Development

Radiotherapy blasts forward

High-wattage takeouts and commercial launches have revived interest in radiopharmaceuticals for cancer. The challenge for the new wave of candidates is to achieve enough differentiation to justify the logistical hurdles of manufacturing and delivering products...
BC Innovations | Jun 7, 2018
Emerging Company Profile

Radio fusion

Fusion Pharmaceuticals Inc. is improving the safety of radiopharmaceuticals for cancer by using a proprietary linker to label antibodies with the radioisotope actinium-225. While the newco remains tight-lipped about the linker’s design, SVP of Business...
BC Week In Review | Dec 8, 2017
Clinical News

Bayer reports mortality signal in Phase III of Xofigo in early CRPC

Bayer AG (Xetra:BAYN) said it will unblind early the Phase III ERA223 trial to treat metastatic castration-resistant prostate cancer (CRPC) after an an IDMC observed more fractures and deaths among patients treated with Xofigo radium-223...
BC Extra | Dec 1, 2017
Clinical News

Bayer reports mortality signal with Xofigo in early CRPC

Bayer AG (Xetra:BAYN) said an IDMC observed more fractures and deaths among patients treated with Xofigo radium-223 dichloride vs. placebo in the Phase III ERA223 trial to treat metastatic castration-resistant prostate cancer. Bayer said it...
BioCentury | Jun 10, 2017
Product Development

Out-thinking industry

Some of the most innovative thinking on display at this year’s American Society of Clinical Oncology meeting came not from cancer companies, but from FDA and groups of oncologists and patient advocates who are busy...
BC Week In Review | Sep 12, 2016
Company News

Bayer sales and marketing update

The U.K.’s NICE issued final draft guidance recommending Xofigo radium-223 dichloride from Bayer to treat castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastases in adults only if docetaxel is not suitable...
BioCentury | Aug 22, 2016
Finance

Northern Lights 2.0

A sea change is taking place in the Scandinavian biotech ecosystem, as an uptick in acquisitions and international investor syndicates shows science coming out of the region's academic institutes is increasingly able to find a...
BC Week In Review | Feb 1, 2016
Company News

Bayer sales and marketing update

The U.K.’s NICE issued final guidance recommending Xofigo radium-223 dichloride from Bayer to treat adults with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastases who have received treatment with docetaxel. The...
BC Extra | Jan 27, 2016
Company News

NICE backs five cancer drugs, spurns Cyramza

The U.K.'s NICE recommended a quintet of cancer drugs, including reversing a prior decision on Farydak panobinostat from Novartis AG (NYSE:NVS; SIX:NOVN); however, the agency snubbed stomach cancer compound Cyramza ramucirumab from Eli Lilly and...
BioCentury | Sep 21, 2015
Regulation

England's cancer problem

Stephen Hansen, Associate Editor   The latest round of cuts from NHS England's Cancer Drugs Fund is leaving some patients without treatment options, and a new system that is expected to be proposed this month...
Items per page:
1 - 10 of 121